Cargando…
Cirrhosis is not a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in highly selected patients
BACKGROUND: Patient selection for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is critically important to optimizing outcomes. There is currently no literature regarding the safety of CRS/HIPEC in patients with cirrhosis. The aim of this case series is to report...
Autores principales: | Weiss, Anna, Ward, Erin P., Baumgartner, Joel M., Lowy, Andrew M., Kelly, Kaitlyn J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922306/ https://www.ncbi.nlm.nih.gov/pubmed/29699564 http://dx.doi.org/10.1186/s12957-018-1389-3 |
Ejemplares similares
-
Preoperative bevacizumab does not increase complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
por: King, Bradley H., et al.
Publicado: (2020) -
Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a prospective clinical trial and comparative analysis
por: Cho, Chae Yun, et al.
Publicado: (2022) -
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer
por: Gamboa, Adriana C., et al.
Publicado: (2019) -
Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy indicated in hepatobiliary malignancies?
por: Leigh, Natasha, et al.
Publicado: (2020) -
Cytoreduction with hyperthermic intraperitoneal chemotherapy: An anaesthetic challenge
por: Murughan, Kavita, et al.
Publicado: (2014)